Peptide Formulation & Delivery

Peptide formulation is the science of converting a raw synthesized peptide into a stable, deliverable product that maintains biological activity and achieves adequate bioavailability at the target site. It is frequently the bottleneck that determines whether a bioactive peptide becomes a useful therapeutic or remains a laboratory curiosity.

The core challenges are intrinsic to peptide chemistry: susceptibility to proteolytic degradation, physical instability (aggregation, oxidation, deamidation), hydrophilicity limiting membrane permeability, and short circulating half-lives. Every formulation strategy addresses one or more of these vulnerabilities.

Lyophilization (freeze-drying)

Lyophilization is the dominant storage form for peptide therapeutics and research peptides. The process removes water from a frozen peptide solution under vacuum (sublimation), producing a dry powder or cake that is reconstituted before use.

Why it matters: peptides are substantially more stable as dry powders than in solution. Aqueous solutions promote hydrolysis, deamidation (particularly at asparagine residues), oxidation (methionine, tryptophan, cysteine), and aggregation. Lyophilized peptides stored at -20 C or below can maintain potency for years.

Key formulation components:

• Cryoprotectants and lyoprotectants — sugars (trehalose, sucrose, mannitol) protect peptide structure during freezing and drying by replacing water hydrogen bonds and forming a glassy matrix
• Bulking agents — mannitol or glycine provide mechanical structure to the lyophilized cake, preventing collapse
• Buffer selection — phosphate buffers can undergo pH shifts during freezing (sodium phosphate drops dramatically). Histidine and citrate buffers maintain pH stability during lyophilization.

Reconstitution is typically performed with bacteriostatic water (containing 0.9% benzyl alcohol) or sterile saline immediately before use.

Liquid formulations

Some peptides are formulated as ready-to-use liquid solutions — eliminating the reconstitution step and improving patient convenience. This requires addressing aqueous instability:

• pH optimization — each peptide has a pH of maximum stability; formulation buffers are selected to maintain this pH
• Antioxidants — methionine or EDTA (as a metal chelator) prevent oxidative degradation
• Preservatives — multi-dose vials require antimicrobial preservatives (phenol, m-cresol, benzyl alcohol). These can interact with the peptide — insulin and GLP-1 agonist formulations require careful compatibility testing with preservatives.
• Tonicity adjusters — sodium chloride or glycerol for physiological osmolality

Insulin pens, liraglutide pens, and semaglutide injection pens are examples of commercially successful liquid peptide formulations.

Subcutaneous injection

The default delivery route for most peptide therapeutics. Subcutaneous (SC) injection provides several advantages: avoidance of first-pass hepatic metabolism, relatively high bioavailability (typically 50-80%), slow absorption from the SC depot (extending effective duration), and patient self-administration capability.

Injection site, volume, and concentration affect absorption kinetics. SC bioavailability varies by peptide — semaglutide achieves approximately 89% SC bioavailability, while some peptides are significantly lower.

Depot formulations

Depot systems encapsulate peptides in biodegradable matrices that release the active compound over weeks to months, enabling infrequent dosing:

• PLGA microspheres — poly(lactic-co-glycolic acid) microspheres are the most established depot technology. Leuprolide depot (Lupron Depot) encapsulates the GnRH agonist in PLGA microspheres for 1-month, 3-month, or 6-month release. The polymer degrades by hydrolysis, gradually releasing the peptide.
• In situ forming gels — liquid formulations that solidify into a gel depot upon injection (triggered by temperature change, solvent exchange, or pH shift). Eligard uses the Atrigel system — leuprolide in an organic solvent/PLGA solution that precipitates into a solid depot upon contact with aqueous tissue fluid.
• Implants — solid polymer rods or cylinders implanted subcutaneously. Histrelin implant (Vantas) provides continuous GnRH agonist release for 12 months.

Depot challenges include initial burst release (a spike of peptide release before steady-state is achieved), peptide stability during encapsulation (organic solvents and polymer interactions can denature peptides), and injection site reactions.

Nasal delivery

Intranasal administration offers a needle-free route with rapid absorption through the highly vascularized nasal mucosa. For neuroactive peptides, the nasal route provides partial CNS access via the olfactory nerve pathway, bypassing the blood-brain barrier.

Clinically used nasal peptides include desmopressin (DDAVP) for diabetes insipidus, calcitonin (Miacalcin) for osteoporosis, oxytocin (Syntocinon) for lactation, and nafarelin (GnRH agonist) for endometriosis. Research peptides Semax and Selank are formulated as nasal drops.

Limitations: bioavailability is typically 1-10% (variable and lower than SC injection), mucociliary clearance rapidly removes formulations from the absorption site, and nasal mucosa can be damaged by chronic use.

Transdermal delivery

Peptides generally cannot cross intact skin — the stratum corneum is a formidable barrier to hydrophilic macromolecules. Strategies to enable transdermal peptide delivery include:

• Microneedle patches — arrays of microscopic needles (100-800 micrometers) that penetrate the stratum corneum and deliver peptide into the epidermis or dermis. Dissolving microneedles made of sugar or polymer matrices release peptide as they dissolve. This technology is under development for insulin, PTH, and GLP-1 agonists.
• Iontophoresis — electrical current drives charged peptides across the skin. Used for some small peptides but limited by molecular weight.

Oral delivery challenges

Oral peptide delivery remains the ultimate pharmacological goal and the greatest formulation challenge. The barriers are well-characterized:

• Gastric acid — pH 1-3 denatures many peptide structures
• Proteases — pepsin, trypsin, chymotrypsin, and brush-border peptidases
• Mucus layer — physical barrier limiting epithelial access
• Epithelial membrane — tight junctions and hydrophobic lipid bilayer block paracellular and transcellular transport

Oral semaglutide (Rybelsus) uses the SNAC permeation enhancer to achieve approximately 1% oral bioavailability — enough for clinical efficacy given semaglutide's high receptor potency, but illustrating how far oral peptide delivery still has to go. Emerging approaches include intestinal-targeting capsules, mucoadhesive nanoparticles, protease inhibitor co-formulation, and ionic liquid peptide formulations.

The formulation route fundamentally shapes a peptide's therapeutic profile — the same molecule can succeed or fail depending on how it is delivered.